RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:3096

Reye syndrome

low confidenceDisorder

Publications

3,763

Trials

0

Interventional, condition-specific

Researchers

931

Distinct authors in sample

Gene link

—

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

A rare, systemic disease characterized by persistent vomiting with confusion, lethargy, disorientation, hyperreflexia, hyperventilation, and tachycardia, with rapid progression to , non-inflammatory , coma and death. It typically develops between 12 hours and 3 weeks after recovery from a viral illness, such as upper respiratory tract infection or gastroenteritis. , acute hepatic steatosis, fatty liver degeneration and multiple laboratory abnormalities are associated.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

Reye's syndrome

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    3,763 matched papers (596 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

3,763

3,763 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

3,763 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

596 in the last 10 years · low confidence

Phrase hits: 3,763 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

931

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Hoption Cann SA5 papers · 2025

    School of Population and Public Health University of British Columbia Vancouver Canada.

    Papers in Europe PMC
  2. 02
    Singh R4 papers · 2025

    Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra 411038, India.

    Papers in Europe PMC
  3. 03
    Antoon JW3 papers · 2023

    Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee.

    Papers in Europe PMC
  4. 04
    Brassier A3 papers · 2026

    Centre de référence des maladies héréditaires du métabolisme, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Institut Imagine, Filière G2M, MetabERN, Paris, France.

    Papers in Europe PMC
  5. 05
    de Lonlay P3 papers · 2026

    INSERM U1151, Institut Necker Enfants-Malades (INEM), Paris, France.

    Papers in Europe PMC
  6. 06
    Schiff M3 papers · 2026

    Université Paris Cité, INSERM, Paris, France.

    Papers in Europe PMC
  7. 07
    Sharma R3 papers · 2024

    Division of Pediatric Critical Care, Advanced Pediatrics Centre, Chandigarh, India.

    Papers in Europe PMC
  8. 08
    Singh RK3 papers · 2025

    Department of Physics, Institute of Science, Banaras Hindu University, Varanasi 221005, India. Electronic address: ranjanksingh65@rediffmail.com.

    Papers in Europe PMC
  9. 09
    Arnoux JB2 papers · 2026

    Reference Centre of Inherited Metabolic Diseases, Necker-Enfants malades Hospital, APHP, Filière G2M, Metab ERN, Université de Paris, Paris, France.

    Papers in Europe PMC
  10. 10
    Bakkaloğlu SA2 papers · 2025

    Department of Paediatric Rheumatology, Gazi University School of Medicine, Ankara, Turkey.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

low confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Reye syndrome" OR "Reye's syndrome"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Reye syndrome" OR "Reye's syndrome"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (3763) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T22:12:58.417Z